Abstract

This project is designed to prepare a GMP quality investigational multicomponent Ebola vaccine and complete the preclinical and laboratory studies needed to begin a clinical trial. Recombinant Adenovirus seroytpe 5 (rAd5) Clinical trial material has been released for use in Phase 1 trials. Additional Ad5 products as well as alternative adenovector vaccines have also been manufactured for preclinical evaluation. Pending the results of these preclinical studies, cGMP products may be manufacturered for clinical trials.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI005053-06
Application #
7732761
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2008
Total Cost
$2,785,478
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Sullivan, Nancy J; Geisbert, Thomas W; Geisbert, Joan B et al. (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3:e177